Overview

STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care

Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
The primary purpose is to describe the safety of administration of three doses of STS to critically ill patients with confirmed COVID-19. A secondary purpose is to describe data on the clinical efficacy of administration of up to three doses of STS in critically ill patients with confirmed COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Hellenic Institute for the Study of Sepsis
Treatments:
Sodium thiosulfate